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Background: Cholera toxin enters the target cell in a disordered state and must attain a folded, active conformation to
modify its G protein target.
Results: Lipid rafts, where G protein is located, shift the disordered toxin to a functional conformation.
Conclusion: Lipids rafts provide a chaperone-like function for cholera toxin.
Significance: Lipid rafts play an important role in regulating toxin function through chaperone-like activity.

Cholera toxin (CT)2 exhibits an ADP-ribosyltransferase
activity against the stimulatory ␣ subunit of the heterotrimeric
G protein (Gs␣) (1). ADP-ribosylation of Arg201 in Gs␣ locks

* This

work was supported by National Institutes of Health Grant R01
AI073783 (to K. T.).
□
S
This article contains supplemental Figs. S1–S5 and Table S1.
1
To whom correspondence should be addressed: Biomolecular Research
Annex, 12722 Research Pkwy., Orlando, FL 32826. Tel.: 407-882-2247; Fax:
407-384-2062; Email: kteter@mail.ucf.edu.
2
The abbreviations used are: CT, cholera toxin; ARF, ADP-ribosylation factor; ␤2AR, ␤2-adrenergic receptor; DEA-BAG, diethylamino(benzylidineamino)guanidine; ER, endoplasmic reticulum; ERAD, ER-associated degradation; LUV, large unilamellar vesicle; PE, phosphatidylethanolamine; PS,
phosphatidylserine.

AUGUST 31, 2012 • VOLUME 287 • NUMBER 36

the GTP-bound protein in an active state that promotes the
continual stimulation of adenylate cyclase and its production of
cAMP. Dysregulation of cAMP-dependent signaling pathways
leads to the opening of apical chloride channels in intoxicated
enterocytes. The osmotic movement of water to counterbalance chloride accumulation in the lumen of the gut consequently generates the profuse, life-threatening diarrhea of
cholera.
CT has an AB5 structural organization that consists of a catalytic A moiety and a homopentameric, cell-binding B moiety
(2). For CT to manifest its latent ADP-ribosyltransferase activity, the CTA polypeptide must be proteolytically nicked to generate separate but disulfide-linked CTA1 and CTA2 subunits
(3, 4). Nicking can involve Vibrio or other proteases. The disulfide bond linking CTA1 to CTA2 must then be reduced (4),
which only occurs after the CT holotoxin moves from the cell
surface to the endoplasmic reticulum (ER) through a series of
vesicle-mediated trafficking steps collectively termed retrograde transport (5, 6). Reduction of the CTA1/CTA2 disulfide
bond permits the chaperone-assisted dissociation of CTA1
from CTA2/CTB5 (7, 8). CTA1 is held in a stable conformation
by its interactions with the holotoxin (9, 10), but the isolated
CTA1 polypeptide is an unstable protein that will spontaneously unfold at 37 °C upon its separation from CTA2/CTB5
(11). The disordered CTA1 polypeptide is subsequently recognized as a misfolded protein by the host quality control system
of ER-associated degradation (ERAD) (12–14). This results in
the ER-to-cytosol translocation of CTA1 through one or
more protein-conducting channels in the ER membrane
(15–18). Most exported ERAD substrates are degraded by
the ubiquitin-proteasome system, but the dearth of CTA1
lysine residues for ubiquitin conjugation allows the toxin to
evade this fate (19, 20).
The translocated pool of CTA1 must regain a folded, active
conformation to modify its Gs␣ target. This will not occur
spontaneously because the isolated CTA1 polypeptide is in a
disordered conformation at 37 °C (11). Host ADP-ribosylation
factors (ARFs) act as allosteric activators of CTA1 and allow the
toxin to exhibit in vitro catalytic activity at 37 °C (21, 22). However, it is possible that other host factors also assist the in vivo
gain of structure and gain of function for cytosolic CTA1.
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Cholera toxin (CT) travels from the cell surface to the endoplasmic reticulum (ER) as an AB holotoxin. ER-specific conditions then promote the dissociation of the catalytic CTA1 subunit from the rest of the toxin. CTA1 is held in a stable
conformation by its assembly in the CT holotoxin, but the dissociated CTA1 subunit is an unstable protein that spontaneously assumes a disordered state at physiological temperature.
This unfolding event triggers the ER-to-cytosol translocation of
CTA1 through the quality control mechanism of ER-associated
degradation. The translocated pool of CTA1 must regain a
folded, active structure to modify its G protein target which is
located in lipid rafts at the cytoplasmic face of the plasma membrane. Here, we report that lipid rafts place disordered CTA1 in
a functional conformation. The hydrophobic C-terminal
domain of CTA1 is essential for binding to the plasma membrane and lipid rafts. These interactions inhibit the temperature-induced unfolding of CTA1. Moreover, lipid rafts could
promote a gain of structure in the disordered, 37 °C conformation of CTA1. This gain of structure corresponded to a gain of
function: whereas CTA1 by itself exhibited minimal in vitro
activity at 37 °C, exposure to lipid rafts resulted in substantial
toxin activity at 37 °C. In vivo, the disruption of lipid rafts with
filipin substantially reduced the activity of cytosolic CTA1.
Lipid rafts thus exhibit a chaperone-like function that returns
disordered CTA1 to an active state and is required for the optimal in vivo activity of CTA1.

A Chaperone-like Activity for Lipid Rafts

EXPERIMENTAL PROCEDURES
Materials—The following were purchased from Avanti
Polar Lipids (Alabaster, AL): cholesterol; palmitoyl sphingomyelin; 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC); 1,2-dioleoyl-sn-glycero-3-phospho-(1⬘-myoinositol) (DOPI); 1,2-dioleoyl-sn-glycero-3-phospho-(1⬘-myoinositol-4⬘-phosphate) (PI(4)P); 1,2-dioleoyl-sn-glycero-3phospho-(1⬘-myoinositol-4⬘,5⬘-bisphosphate) (PI(4,5)P2);
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine
(PLPE); 1-palmitoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine
(PLPS); 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(SAPC); 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (SAPE); 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (SLPE); 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC); and pyrene-labeled PE (pyrene-PE). Filipin was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); CT
was purchased from List Biologicals (Campbell, CA); and isoproterenol was purchased from Sigma-Aldrich. CTA1 with a C-terminal His6 tag was purified as described previously (13) and used
for all in vitro studies.
Composition and Generation of Large Unilamellar Vesicles
(LUVs)—The plasma membrane lipid profile of the rat intestinal epithelium (30 –34) was used as the basis for the acyl chain
and head group composition of our plasma membrane mimic.
Asymmetric lipid distributions between the inner and outer
bilayer leaflets (35–37) were further considered to specifically
model the composition of the inner leaflet of the plasma membrane (Table 1). To simulate the composition of a lipid raft
(38 – 41), we mixed sphingomyelin and cholesterol with zwitterionic PE and anionic PS (Table 1). The latter two lipids are
highly enriched in the inner leaflet of a lipid raft (42– 45). Acyl
chain selection was based upon the intestinal lipid composition.
The inner leaflet of a lipid raft may lack sphingomyelin (46), so
we formulated an alternative lipid raft mimic that lacked
sphingomyelin (Table 1).
Individual lipids were dissolved in chloroform and mixed
according to the percentages listed in Table 1. The total lipid
concentration was 8 mM. The solvent was evaporated under a
slow stream of nitrogen gas and vacuum dried for 4 h. The dried
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TABLE 1
Lipid composition of LUVs mimicking the plasma membrane or lipid
rafts
Percentage of composition
Lipid
Cholesterol
PLPS
Palmitoyl sphingomyelin
PLPE
SLPE
SAPE
SOPC
SAPC
PI(4,5)P2
PI(4)P
DOPI
PLPC

Plasma membrane

Lipid
raft

Variant lipid
raft

0
13
4
27
14
5
20
14
1
1
1
0

30
15
30
25
0
0
0
0
0
0
0
0

30
15
0
45
0
0
0
0
0
0
0
10

mixture was suspended in 10 mM borate buffer (pH 7.0) containing 100 mM NaCl and vortexed thoroughly. To generate
LUVs, the lipid mixture was passed 30 times through a Liposofast extruder (Avestin, Ottawa, ON, Canada) with 100-nm pore
size polycarbonate membranes.
Membrane-binding Experiments—To detect CTA1 interaction with LUVs mimicking the composition of the plasma
membrane or lipid rafts, we added 1% pyrene-PE to the vesicles.
CTA1 was titrated with pyrene-PE-labeled vesicles in a 4 ⫻
4-mm2 path length quartz cuvette, and membrane binding of
CTA1 was measured based on fluorescence resonance energy
transfer (FRET) from the three tryptophan (Trp) residues of
CTA1 to pyrene-PE using a Jasco 810 spectrofluoropolarimeter
(Tokyo, Japan). This is a spectropolarimeter equipped with a
Jasco PFD-425S Peltier temperature controller and an additional photomultiplier tube mounted at a right angle, which
permits fluorescence measurements in addition to CD. Experiments were performed using a final sample volume of 220 l
containing 15 M CTA1 in the presence or absence of LUVs,
with excitation wavelength of 290 nm. The FRET data were
analyzed as described previously (47). Briefly, changes in Trp
fluorescence at each addition of pyrene-PE-containing vesicles
(⌬F) were measured and plotted against ⌬F/[L], where [L] is the
total lipid concentration. These Scatchard plots were used to
determine the limiting value of ⌬F, i.e. ⌬Fmax. Protein binding
isotherms were constructed by plotting ⌬F/⌬Fmax against [L],
after correction of ⌬F values for the sample dilution effects and
for the changes in ⌬F in negative control experiments where the
protein was titrated with vesicles without pyrene-PE. Using a
Langmuir-type binding model (the membrane surface contains
protein binding sites that bind the protein with a dissociation
constant of KD and a lipid-to-protein stoichiometry of N lipids/
protein), values of KD and N were determined from best fits of
simulated and experimental binding isotherms.
CD and Fluorescence Spectroscopy—A Jasco 810 spectrofluoropolarimeter was used for CD measurements of samples
placed in a 4-mm path length quartz cuvette. Experiments were
performed using a final sample volume of 220 l containing 15
M CTA1 in the presence or absence of 800 M LUVs. Light
scattering effects became significant only below 205 nm in
experiments with CTA1 and below 210 –215 nm in experiments utilizing LUVs at 800 M lipid concentration (e.g. see Fig.
2). The characteristic spectral minima of CD spectra which
VOLUME 287 • NUMBER 36 • AUGUST 31, 2012
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In this paper, we examined the impact of lipid rafts on the
structure and function of CTA1. Gs␣ is found in lipid rafts at the
cytosolic face of the plasma membrane (23–26). CTA1 would
therefore encounter a lipid raft environment upon contact with
its Gs␣ target. Because two major components of lipid rafts
(cholesterol and phosphatidylethanolamine (PE)) can act as
lipochaperones (27–29), we hypothesized an interaction with
lipid rafts would shift disordered CTA1 to a folded, active conformation. Structural analysis with circular dichroism (CD) and
functional analysis with an in vitro ADP-ribosylation assay supported our hypothesis: exposure to lipid rafts but not plasma
membrane lipids allowed the disordered CTA1 subunit to
attain a folded structure and enzymatic activity at 37 °C. The
physiological relevance of these observations was documented
with an in vivo intoxication assay which demonstrated intact
lipid rafts are required for the ADP-ribosylation of Gs␣ by cytosolic CTA1. Lipid rafts thus display a chaperone-like activity
that modulates the structure and function of CTA1.

A Chaperone-like Activity for Lipid Rafts

X ⫽ f LX L ⫹ 共 1 ⫺ f L兲 X H

(Eq. 1)

where X is the measured temperature-dependent variable (i.e.
the ellipticity or peak fluorescence emission wavelength), fL is
the fraction of amino acids representing the native conformation at low temperature, XL is the limiting value of X at low
temperature, and XH is the limiting value of X at high temperature. The parameter, fL, is given by:
fL ⫽

exp共⫺⌬G/RT兲
1 ⫹ exp共⫺⌬G/RT兲

(Eq. 2)

The free energy of unfolding (⌬G) is given by
⌬G ⫽ ⌬H 共 1 ⫺ T/T m 兲 ⫹ ⌬C 关 T⫺Tm⫺T In共T/Tm兲兴 (Eq. 3)
Here, ⌬H is the apparent enthalpy of unfolding and ⌬C (0.39
kcal mol⫺1 K⫺1) is the heat capacity of unfolding.
To monitor the potential renaturation of disordered CTA1
by plasma membrane or lipid raft LUVs, far- and near-UV CD
measurements of CTA1 structure were taken at 18 °C. Plasma
membrane or lipid raft LUVs were added to a final lipid concentration of 800 M after heating the toxin to 37 °C. The temperature was maintained at 37 °C, and CD spectra were
recorded 5 or 30 min after exposure to the LUVs.
In parallel control experiments, CD and fluorescence measurements were recorded at each temperature in the presence of
LUVs alone (plasma membrane, lipid raft, or variant lipid raft).
CD and fluorescence spectra of the CTA1 samples were then
corrected by subtraction of the appropriate temperaturematched spectra of LUVs only. Sphingomyelin produces a
strong far-UV CD signal below 200 nm (i.e. between 195 and
197 nm), but around 220 nm its contribution to the far-UV CD
signal is only 4 –5% of the protein contribution (49). The minimal contribution of sphingomyelin to the 220 nm far-UV CD
signal of CTA1 was eliminated by the aforementioned background subtraction procedure before calculating the CTA1
secondary structure Tm at 220 nm.
In Vitro Assay for CTA1 Catalytic Activity—Diethylamino(benzylidine-amino)guanidine (DEA-BAG) is a CTA1 subAUGUST 31, 2012 • VOLUME 287 • NUMBER 36

strate that loses its ability to bind AG-50W-X4 ion exchange
resin (Bio-Rad) after ADP-ribosylation (50). DEA-BAG also
exhibits an intrinsic fluorescence (361-nm excitation wavelength, 440-nm emission wavelength), so the fluorescent signal
remaining after pulldown with AG-50W-X4 resin represents
the ADP-ribosylated pool of DEA-BAG. 2-fold serial dilutions
of CTA1 were placed in 200 l of KH2PO4 buffer (pH 7.5) containing 20 mM DTT, 10 mM NAD, and 0.1 mg/ml BSA. In a
subset of samples, lipid raft LUVs were also added to a final lipid
concentration of 800 M. LUVs were added at 25 °C or after the
toxin had been heated to 37 °C for 30 min. When added after
heating, LUVs were incubated with the toxin for 1 h at 37 °C
before addition of the DEA-BAG substrate. All toxin samples
were incubated with 0.4 mg of DEA-BAG for 2 h at either 25 °C
or 37 °C as indicated. After batch removal of unmodified DEABAG with 800 l of a 40% AG-50W-X4 resin slurry, fluorescence intensity in the supernatant was recorded with a Biotek
(Winooski, VT) Synergy 2 plate reader.
Cell Culture Studies—HeLa cells seeded to 80% confluence in
6-well plates were transfected with 0.5 g of pcDNA3.1/
mCTA1 (51) using a 5-h exposure to Lipofectamine (Invitrogen) according to the manufacturer’s instructions. Transfected
cells were chased in the absence or presence of filipin (1 g/ml)
for 2 or 4 h before cAMP levels were quantified using a commercial kit (PerkinElmer Life Sciences). Three samples per condition were run for each experiment. Background levels of
cAMP from mock-transfected cells were subtracted from all
results before expressing the data as percentages of the maximum cAMP signal obtained for the experiment.
CHO cells stably transfected with a gene encoding the ␤2-adrenergic receptor (␤2AR) were provided by Dr. S. E. Mills (52,
53). Before quantification of cAMP levels, untreated and filipintreated CHO-␤2AR cells were incubated for 4 h with 100 ng/ml
CT or 1 M ␤2AR agonist isoproterenol. Filipin was co-incubated with CT or isoproterenol and was used at a concentration
of 1 g/ml. In each experiment, three samples were run for each
condition. The basal levels of cAMP from untreated cells were
subtracted from all results before expressing the data as percentages of the maximum cAMP signal obtained for the
experiment.

RESULTS
CTA1 Binds to Lipid Rafts—Toxin-lipid interactions were
initially examined by FRET (Fig. 1). CTA1 was incubated at
37 °C with LUVs mimicking the composition of either the
plasma membrane or lipid rafts (Table 1). LUVs were prepared
using 1% pyrene-PE at the expense of PLPE. Binding of CTA1 to
the pyrene-PE-containing membrane results in short range
dipolar interactions between the energy donor (Trp) and the
acceptor (pyrene-PE), thus decreasing Trp emission intensity
between 300 and 360 nm and increasing the 360 – 450 nm emission intensity of pyrene-PE. This FRET effect was observed
when CTA1 was mixed with vesicles mimicking either the
plasma membrane (Fig. 1A) or lipid rafts (Fig. 1B). As expected,
increasing the LUV concentration produced a concomitant
decrease in the Trp emission intensity. No substantial alteration to the CTA1 emission intensity was recorded when the
toxin was incubated with plasma membrane (Fig. 1C) or lipid
JOURNAL OF BIOLOGICAL CHEMISTRY
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were used for Tm determination (see below) were not affected
by light scattering effects at this lipid concentration. To monitor the potential stabilizing effect of plasma membrane or lipid
raft LUVs on CTA1 structure, near-simultaneous measurements of far-UV CD, near-UV CD, and fluorescence were taken
as the temperature was increased stepwise from 20 °C to 60 °C.
The temperature was ramped from 20 °C to 34 °C in 2 °C increments; from 34 °C to 40 °C in 1 °C increments, and from 40 °C
to 60 °C in 2 °C increments. At each temperature, the sample
was equilibrated for 4 min before measurement. The experimentally measured ellipticities (obs) were converted to mean
residue molar ellipticity, [], by using the following formula:
[] ⫽ obs/cnl, where n is the number of amino acid residues in
the protein, c is the molar concentration of the protein, and l is
the path length of the cuvette in millimeters.
Calculations of transition temperatures (Tm; the midpoint
between folded and final disordered states) were performed as
described previously (11). In brief, data were analyzed using the
following equation (48):

A Chaperone-like Activity for Lipid Rafts

raft (Fig. 1D) LUVs lacking the pyrene-PE acceptor. The loss of
CTA1 fluorescence intensity in Fig. 1, A and B, was therefore
due to FRET between CTA1 and a membrane containing a
pyrene-PE acceptor. Further data analysis was used to calculate
a 2.3 M KD for CTA1 binding to plasma membrane LUVs (Fig.
1E) and a 0.6 M KD for CTA1 binding to lipid raft LUVs (Fig.
1F). CTA1 thus binds to both the plasma membrane and lipid
rafts, but it has a higher affinity for lipid rafts.
The C-terminal A13 subdomain of CTA1 was initially
thought to activate the ERAD system because this region contains a number of hydrophobic amino acid residues that could
have allowed the toxin to masquerade as a misfolded protein
(20). Subsequent studies found that the A13 subdomain is not
essential for toxin translocation (54), but we hypothesized that
this hydrophobic region is instead responsible for CTA1 binding to lipid bilayers. A CTA1 construct lacking the A13 subdomain (CTA11–168) was used to test this prediction. As shown
in supplemental Fig. S1, CTA11–168 did not interact with either
plasma membrane or lipid raft LUVs. CTA11–168 maintains the
same stability and the same general structure as full-length
CTA1 (12, 55), so the loss of binding affinity could not be attributed to structural alterations in CTA11–168. Thus, the hydrophobic A13 subdomain of CTA1 appeared to mediate toxinlipid interactions directly.
Stabilization and Renaturation of CTA1 by Lipid Rafts—We
next examined the structural impact of CTA1 binding to either
the plasma membrane or lipid rafts. For this work, the thermal
stability of CTA1 in the absence or presence of lipid bilayers
was examined by CD and fluorescence spectroscopy (Fig. 2).

30398 JOURNAL OF BIOLOGICAL CHEMISTRY

CTA1 was mixed with LUVs mimicking the composition of the
plasma membrane or lipid rafts at 20 °C, and measurements
were taken during a stepwise increase in temperature from
20 °C to 60 °C. Additional measurements were taken with a
CTA1 sample heated in the absence of LUVs. The collective
data demonstrated that interactions with plasma membrane
and lipid raft LUVs have moderate and prominent stabilizing
effects on CTA1, respectively. In the absence of LUVs, CTA1
exhibited a secondary structure transition temperature Tm of
34 °C (Fig. 2A), a tertiary structure Tm of 31 °C (Fig. 2B) derived
from CD measurements, and a 34 °C Tm for the red shift to the
maximum emission wavelength (max) of Trp fluorescence (Fig.
2C). In the presence of plasma membrane LUVs, CTA1 exhibited a secondary structure Tm of 39 °C (Fig. 2D), a tertiary structure Tm of 37 °C (Fig. 2E), and a 37 °C Tm for the max of Trp
fluorescence (Fig. 2F). These values were similar to the corresponding Tm values recorded for CTA1 in the presence of LUVs
mimicking the composition of the ER membrane (56), which
suggests that toxin-lipid interactions may have a general stabilizing effect on the structure of CTA1. However, a substantially
greater degree of stabilization was observed when CTA1 was
exposed to lipid raft LUVs. For this condition, CTA1 exhibited
a secondary structure Tm of 47 °C (Fig. 2G), a tertiary structure
Tm of 45 °C (Fig. 2H), and a 44 °C Tm for the max of Trp fluorescence (Fig. 2I). These Tm values were 10 –14 °C higher than
the values obtained for untreated CTA1 and 7– 8 °C higher than
the values recorded for CTA1 in the presence of plasma membrane LUVs, indicating a profound increase in CTA1 thermal
stability upon interaction with membranes mimicking lipid
VOLUME 287 • NUMBER 36 • AUGUST 31, 2012
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FIGURE 1. CTA1 binds to plasma membrane and lipid raft LUVs. The affinity between CTA1 and the plasma membrane (A, C, and E) or lipid rafts (B, D, and F)
was determined by tryptophan FRET using pyrene-labeled LUVs (A and B) or unlabeled LUVs (C and D). For the representative spectra in A–D, a change of color
from blue to red signifies an increase in lipid concentration from 100 to 1000 M. Each measurement of fluorescent intensity for both labeled and unlabeled
LUVs was normalized to the CTA1 concentration at the start of the experiment (i.e. corrections were made for the sample dilution effect). In E and F, the solid lines
were constructed using a Langmuir-type binding model, and KD values were calculated from curve fitting as described under “Experimental Procedures.”

A Chaperone-like Activity for Lipid Rafts
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FIGURE 2. CTA1 is stabilized by its interaction with plasma membrane and lipid raft LUVs. The temperature-induced unfolding of CTA1 (A–C), CTA1 in the
presence of plasma membrane LUVs (D–F), and CTA1 in the presence of lipid raft LUVs (G–I) was recorded by far-UV CD (A, D, and G), near-UV CD (B, E, and H),
and fluorescence spectroscopy (C, F, and I). The change in color from blue to red denotes the increase in temperature from 20 °C to 60 °C. J–L, thermal unfolding
profiles for CTA1 (red), CTA1 in the presence of plasma membrane LUVs (blue), and CTA1 in the presence of lipid raft LUVs (orange) were derived from the data
presented in A–I. J, for far-UV CD analysis, the mean residue molar ellipticities at 220 nm ([]220) were plotted as a function of temperature. K, for near-UV CD
analysis, the mean residue molar ellipticities at 280 nm ([]280) were plotted as a function of temperature. L, for fluorescence spectroscopy, the maximum
emission wavelength (max) was plotted as a function of temperature. One of two independent experiments is shown for each condition.

rafts. The thermal unfolding profiles for each of our biophysical
measurements are shown in Fig. 2, J–L, and the calculated Tm
values are summarized in Table 2. Neither plasma membrane
nor lipid raft LUVs affected the thermal unfolding of
AUGUST 31, 2012 • VOLUME 287 • NUMBER 36

CTA11–168 (supplemental Fig. S2 and Table S1), which exhibits
the same conformational stability as full-length CTA1 (12). Lipid-induced alterations to the structure of CTA1 thus required a
direct interaction with the toxin.
JOURNAL OF BIOLOGICAL CHEMISTRY
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A Chaperone-like Activity for Lipid Rafts
CTA1 enters the cytosol in an unfolded state and must therefore regain an active, folded conformation to modify its Gs␣
target. We hypothesized that an interaction with lipid rafts
would facilitate renaturation of the disordered CTA1 polypeptide. Far- and near-UV CD were used to test this prediction
(Fig. 3). CTA1 was placed at 18 °C, and measurements of toxin
structure were recorded. The toxin was subsequently heated to
TABLE 2
CTA1 stability in the presence of plasma membrane or lipid raft LUVs
Values represent the averages ⫾ ranges from two independent experiments as represented by the data in Fig. 2 and supplemental Fig. S3.
Tm
Toxin condition

Far-UV CD
°C

34 ⫾ 1
39 ⫾ 2
47 ⫾ 2
45 ⫾ 1

°C

31 ⫾ 1
37 ⫾ 1
45 ⫾ 2
41 ⫾ 1

Fluorescence
spectroscopy
°C

34 ⫾ 1
37 ⫾ 1
44 ⫾ 1
41 ⫾ 1

FIGURE 3. Partial refolding of CTA1 by lipid raft LUVs. CD was used to monitor the structure of CTA1. Measurements of untreated CTA1 were taken at 18 °C
(solid lines). The toxin was subsequently heated to 37 °C and then left untreated (A and B), exposed to plasma membrane LUVs (C and D), or exposed to lipid raft
LUVs (E and F). Additional near-UV CD (A, C, and E) and far-UV CD (B, D, and F) measurements were taken 5 (dotted lines) and 30 (dashed lines) min after a
continued 37 °C incubation in the absence or presence of LUVs. One of three representative experiments is shown.
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Untreated
⫹Plasma membrane
⫹Lipid raft
⫹Variant lipid raft

Near-UV CD

37 °C. The disordered CTA1 polypeptide was then left
untreated, was mixed with plasma membrane LUVs, or was
mixed with lipid raft LUVs. Further measurements of toxin
structure were recorded after an additional 5 min and 30 min at
37 °C. In the absence of LUVs, CTA1 progressed to an increasingly disordered state (Fig. 3, A and B). The presence of plasma
membrane LUVs prevented the additional time-dependent loss
of CTA1 structure but did not promote a gain of secondary or
tertiary structure (Fig. 3, C and D). In contrast, CTA1 shifted to
a more ordered state in the presence of lipid raft LUVs (Fig. 3, E
and F). After 30 min at 37 °C in the presence of lipid rafts, the
initially disordered CTA1 polypeptide displayed a microenvironment around its aromatic amino acid residues that was similar to the folded, 18 °C toxin conformation (Fig. 3E). The initial
temperature-dependent loss of CTA1 secondary structure was
also reversed in the presence of lipid rafts. However, the gain of
CTA1 secondary structure was incomplete: the far-UV CD signal for raft-treated toxin was weaker than the initial 18 °C signal

A Chaperone-like Activity for Lipid Rafts
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FIGURE 4. CTA1 activity in the presence of lipid raft LUVs. 2-fold dilutions
of CTA1 were mixed with lipid raft LUVs at 25 °C for toxicity assays performed
at 25 °C (open squares) or 37 °C (filled squares). For a third condition, LUVs were
added after the toxin had been heated to 37 °C for 30 min (filled triangles). This
toxin-LUV mixture was incubated at 37 °C for an additional hour before initiating the toxicity assay. Toxin samples incubated in the absence of LUVs at
25 °C (open circles) or 37 °C (filled circles) were also used for the assay. Four
samples were used for each condition; results are presented as means ⫾ S.E.
(error bars). One of three representative experiments is shown.

In Vivo Contribution of Lipid Rafts to G Protein and CTA1
Function—Gs␣ is found in lipid rafts on the cytoplasmic face of
the plasma membrane (23–26). CTA1 would thus encounter a
lipid raft environment upon contact with its Gs␣ target. This
suggests that lipid rafts could contribute to CT intoxication by
facilitating the return of disordered CTA1 to a folded, active
conformation. To examine this possibility, we monitored the
enzymatic activity of CTA1 in filipin-treated cells. Filipin
blocks CT intoxication by disrupting the lipid rafts which are
required for endocytosis and intracellular trafficking of CT
(57). To circumvent the upstream roles of lipid rafts in CT
intoxication, we used a plasmid-based system (51) for direct
expression of CTA1 in the cytosol of cells with intact or filipindisrupted lipid rafts. At 2 and 4 h after transfection, filipintreated cells exhibited substantially lower levels of cAMP than
the untreated control cells (Fig. 5). Preliminary control experiments ensured that filipin did not alter the level of protein synthesis in drug-treated cells (data not shown), so the low levels of
cAMP in filipin-treated cells could not be attributed to the lack
of plasmid-borne CTA1 expression. Additional control experiments found that filipin treatment had a moderate, direct
effect on Gs␣ signaling events: when treated with isoproterenol,
a ligand for the G-coupled ␤2AR (52, 53), CHO-␤2AR cells produced a robust cAMP response that was reduced by 20% in the
presence of filipin. In contrast, filipin reduced the cAMP
response from CTA1-expressing cells by 50% at 2 h after transfection and 65% at 4 h after transfection (Fig. 5). The greater
extent of inhibition for CTA1-generated cAMP versus isoproterenol-generated cAMP indicated a direct inhibitory effect of
filipin on the cytosolic activity of CTA1. Thus, lipid rafts appear
to be essential for the optimal in vivo ADP-ribosyltransferase
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for folded CTA1 and was red-shifted by 4 nm from 220 to 224
nm, indicating the movement of amino acid residues into a
more hydrophobic environment (Fig. 3F). A further 30-min
incubation at 37 °C, for a total of 1 h in the presence of lipid raft
LUVs, did not induce a further gain of structure in the CTA1
polypeptide (data not shown). These observations indicated
that an interaction with lipid rafts at physiological temperature
will promote a partial restoration of structure for the disordered CTA1 polypeptide.
Sphingomyelin may be largely restricted to the outer leaflet
of a lipid raft (46), so we repeated our structural studies with
variant lipid raft LUVs devoid of sphingomyelin (Table 1). The
alternative, sphingomyelin-depleted lipid rafts also stabilized
CTA1 when mixed with the toxin at 20 °C (supplemental Fig.
S3) and induced a gain of CTA1 structure when mixed with the
disordered toxin at 37 °C (supplemental Fig. S4). The stabilization of CTA1 by sphingomyelin-depleted lipid rafts was less
prominent than that observed for sphingomyelin-containing
lipid rafts but was still more substantial than the stabilization
provided by plasma membrane lipids (Table 2). Moreover,
sphingomyelin-depleted lipid rafts but not plasma membrane
lipids could promote a gain of structure in disordered CTA1.
These collective observations indicated that the presence of
sphingomyelin is not critical for the dramatic structural alterations to CTA1 that result from its interaction with lipid rafts.
CTA1 Activity at Physiological Temperature Is Enhanced by
Lipid Rafts—The isolated CTA1 polypeptide has little to no
enzymatic activity at 37 °C (22), which is consistent with the
disordered conformation it assumes at physiological temperature (11). We hypothesized the stabilization and renaturation of
CTA1 by lipid rafts would allow the toxin to manifest its enzymatic function at 37 °C. This prediction was tested using DEABAG, a synthetic substrate for the ADP-ribosyltransferase
activity of CTA1 (50). At 25 °C, we documented the dose-dependent modification of DEA-BAG by CTA1 (Fig. 4). A minimal signal was recorded at 37 °C, and this signal most likely
represented a background reading because it did not increase
with increasing toxin concentration. However, a substantial
signal was detected when CTA1 was mixed with lipid raft LUVs
before warming to 37 °C. The stabilizing effect of lipid rafts thus
allowed CTA1 to maintain enough of its native structure, and
hence activity, to effectively modify the DEA-BAG substrate.
Moreover, CTA1 exhibited high levels of ADP-ribosylation
activity when lipid raft LUVs were added after the toxin had
been warmed to 37 °C. An interaction with lipid rafts thus
shifted the disordered, 37 °C conformation of CTA1 to an
active state. However, lipid rafts did not enhance the activity of
folded CTA1 at 25 °C. The raft-induced gain of CTA1 function
thus appeared to result from a gain of structure in disordered
CTA1 rather than from allosteric activation of the toxin: if lipid
rafts acted as an allosteric activator for CTA1, we would have
also detected raft-stimulated toxin activity at 25 °C. These
results were obtained with both sphingomyelin-containing
lipid raft LUVs (Fig. 4) and sphingomyelin-depleted lipid raft
LUVs (supplemental Fig. S5). Thus, sphingomyelin was not
required for the raft-induced gain of CTA1 function at 37 °C.
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activity of CTA1. Our in vitro biophysical and biochemical
studies strongly suggest that the essential function of lipid rafts
is linked to their chaperone-like ability to place disordered
CTA1 in a folded, active conformation at 37 °C.

DISCUSSION
To reach its G protein target, CTA1 undergoes what has been
termed an order-disorder-order transition (55). The ordered
CTA1 polypeptide travels from the cell surface to the ER as part
of an intact holotoxin (6). Separation of CTA1 from CTA2/
CTB5 in the ER releases the structural constraints on CTA1
unfolding and allows the dissociated CTA1 subunit to spontaneously assume a disordered conformation at physiological
temperature (11). This unfolding event identifies CTA1 as a
substrate for ERAD-mediated translocation to the cytosol (12–
14, 58, 59). The translocated, cytosolic pool of CTA1 must then
interact with one or more host factors to regain an ordered
conformation. We have previously focused on the order-todisorder transition that occurs in the ER. Here, we demonstrate
lipid rafts play an active role in the disorder-to-order transition
for cytosolic CTA1.
As documented with biophysical and biochemical assays,
lipid rafts induced disordered CTA1 to assume an ordered,
functional conformation. Lipid rafts thus exhibit a chaperonelike activity for CTA1. In vivo disruption of lipid rafts with filipin further demonstrated the physiological importance of this
chaperone-like function, because the enzymatic activity of
cytosolic CTA1 was greatly attenuated in filipin-treated cells.
PE, a major component of the lipid raft inner membrane and
the bacterial plasma membrane, is known to exhibit a
“lipochaperone” function in the biogenesis of the polytopic bac-
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FIGURE 5. Lipid rafts are required for optimal in vivo activity of cytosolic
CTA1. HeLa cells were transfected with a plasmid encoding a CTA1 construct
that is expressed directly in the cytosol. Intracellular cAMP levels at 2 and 4 h
after transfection were then quantified for untreated and filipin-treated cells.
The averages ⫾ S.D. (error bars) of 3– 4 independent experiments with triplicate samples are shown.

terial protein lactose permease (29). Dimyristoylphosphatidylethanolamine can likewise induce denatured horseradish peroxidase to attain a folded, active conformation (27). In addition,
cholesterol but not sphingolipid has been linked to the proper
folding and maturation of cellular prion protein in the ER (28).
Because multiple components of the lipid raft inner membrane
can modulate protein structure, the chaperone-like activity
observed for raft-CTA1 interactions could be a common phenomenon for raft-associated proteins.
Association of the CTB pentamer with its GM1 receptor
results in toxin/ganglioside clustering in lipid rafts and subsequent internalization to the endosomal system. Continued
interaction with the raft-associated GM1 then directs CT from
the endosomes to the trans-Golgi network en route to the ER
translocation site (6). Disruption of lipid rafts with filipin or
methyl-␤-cyclodextrin thus protects cultured cells from intoxication by inhibiting the endocytosis and intracellular transport
of CT (57, 60). Given that CT delivery to the ER is dependent
upon lipid rafts, the other important function of lipid rafts (i.e.
modulation of cytosolic CTA1 structure/function) has gone
undetected. We were able to document the in vivo chaperonelike function of lipid rafts toward CTA1 by directly producing
CTA1 in the cytosol of cells transfected with the pcDNA3.1/
mCTA1 expression vector. This bypassed the upstream raftdependent CT trafficking events and allowed us to demonstrate
an additional role for lipid rafts in the intoxication process.
However, the cytosolic pool of transfected CTA1 still exhibited
some activity in filipin-treated cells. This suggests that other
components of the host cytosol, such as ARF proteins, could
also contribute to the in vivo renaturation of disordered CTA1.
In previous work, filipin was applied to Caco-2 cells at various postintoxication time intervals (57). The inhibitory effect of
filipin diminished with longer postexposure delays in drug
treatment, which suggested that filipin only affected early steps
in the intoxication process. However, this procedure could not
determine how much CTA1 had already reach Gs␣ at the time
of drug treatment. The use of a cAMP phosphodiesterase inhibitor would further stabilize any cAMP that had already been
produced at the time of drug treatment. Our plasmid-based
system provided an alternative method to disrupt lipid rafts
before CTA1 appearance/expression in the cytosol. Data generated from this approach indicated that the optimal activity of
cytosolic CTA1 requires intact lipid rafts, which was consistent
with our in vitro biophysical and biochemical analysis of CTA1raft interactions.
LUVs mimicking the composition of the ER (56) or plasma
membrane provide a stabilizing environment for the labile
structure of CTA1. However, lipid raft LUVs provide a substantially greater stabilizing environment than either ER or plasma
membrane LUVs. Moreover, the gain of structure for disordered CTA1 is a raft-specific event. Because Gs␣ is present in
lipid rafts (23–26), CTA1 would benefit from the chaperonelike function of lipid rafts upon contact with its G protein target. The resulting gain of structure confers a basal level of activity to CTA1 without acting through allostery because no gain of
function was recorded for CTA1 treated with lipid rafts at
25 °C. Host ARF proteins instead act as allosteric activators of
CTA1 by inducing a conformational change in CTA1 which
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allows NAD (the donor molecule for the ADP-ribosylation
reaction) to readily access the toxin active site (21, 61). Ongoing
studies are examining the relative contributions of lipid rafts
and ARF proteins to CTA1 activity.
CTA1 exhibited a 2.3 M affinity for the plasma membrane
and a stronger 0.6 M affinity for lipid rafts. This differential
affinity suggests a possible mechanism for CTA1 delivery to
raft-localized Gs␣. The translocated pool of CTA1 appears to
reach its Gs␣ target by diffusion through the cytosol (51). Binding to the plasma membrane would capture cytosolic CTA1
and place it in the general vicinity of Gs␣. The membrane-associated CTA1 subunit would then undergo lateral diffusion
along the inner leaflet of the plasma membrane and eventually
accumulate in the much smaller surface area of lipid rafts, as it
has a higher affinity for lipid rafts than the bulk plasma membrane. A two-stage diffusion trap involving an initial binding to
the bulk plasma membrane and a subsequent partitioning into
lipid rafts would improve the probability of toxin-target interactions compared with a Gs␣ contact mechanism involving
random toxin diffusion through the cytosol. Sequential interactions with the plasma membrane and lipid rafts would also
serve to first stabilize and then refold the disordered, cytosolic
CTA1 polypeptide.
The hydrophobic A13 subdomain at the C terminus of CTA1
is responsible for toxin binding to lipid bilayers. Thus, although
it is not required for ERAD-mediated toxin translocation (54),
the A13 subdomain still plays a functional role in host-toxin
interactions. C-terminal domains from the catalytic subunits of
Shiga toxin and ricin, two other ER-translocating toxins, also
interact with lipid bilayers and play important roles in intoxication (62– 65). For ricin A chain, the C terminus has been
shown to mediate an interaction with the negatively charged
phospholipids of the ER membrane which results in toxin
unfolding (62, 63). This would place ricin A chain in a translocation-competent conformation for ERAD-mediated export to
the cytosol. The available data suggest a similar mechanism for
translocation of the Shiga toxin A1 subunit (64 – 66), although
this model has yet to be directly addressed. An early model of
ERAD-mediated toxin translocation noted that multiple ERtranslocating toxins contain A chains with hydrophobic C termini and suggested that this could allow the toxin A chains to
masquerade as ERAD substrates (20). It now appears that the C
termini of toxin A chains, at least for CTA1, ricin A chain, and
Shiga toxin A1 chain, play a common role in intoxication. However, rather than serving as a direct trigger for ERAD activation,
the C termini seem to facilitate toxin-lipid interactions that
promote either toxin unfolding in the ER or toxin refolding in
the cytosol.
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